Traders should monitor upcoming NDA module submissions, particularly the clinical data package in Q2 2026, and any announcements regarding U.S. commercial partnerships, which could serve as additional positive catalysts. Approval would position D-PLEX100 as a first-in-class localized antibiotic therapy with high commercial potential.
Price Chart
Executive Summary
PolyPid Ltd. has initiated a rolling New Drug Application (NDA) submission to the FDA for its lead product candidate D-PLEX100, aimed at preventing surgical site infections in colorectal surgery patients. This milestone follows Fast Track and Breakthrough Therapy designations and positive Phase 3 trial results showing a 60% reduction in infection risk.
Key Facts
- PolyPid initiated a rolling NDA submission to the FDA for D-PLEX100 under Fast Track designation.
- The submission includes CMC and nonclinical modules, with clinical data expected in Q2 2026.
- D-PLEX100 demonstrated a statistically significant 60% relative risk reduction in surgical site infections in the Phase 3 SHIELD II trial (p = 0.0013).
- The product has received both FDA Fast Track and Breakthrough Therapy Designations.
- U.S. commercialization partnership discussions are ongoing.
Financial Impact
Potential multi-hundred-million-dollar revenue opportunity if approved; could significantly increase company valuation given current $80M market cap.
Risk Factors
- FDA may request additional data or delay approval despite Fast Track status.
- Clinical section of NDA may reveal safety or efficacy concerns not evident from Phase 3 top-line results.
- Failure to secure a U.S. commercial partner could limit market penetration and revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-036923 |
| Document: ea028428801ex99-1.htm | 0001213900-26-036923 |
| Document: 0001213900-26-036923-index-headers.html | 0001213900-26-036923 |
| Document: 0001213900-26-036923-index.html | 0001213900-26-036923 |
| Document: 0001213900-26-036923.txt | 0001213900-26-036923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $4.90 | awaiting T+60 | — | $5.29 (+7.96%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.29 (+10.67%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.29 (+29.66%) |
Jul 21, 2026 13w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.29 (+41.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers